Long-term safety and efficacy of deferasirox in young pediatric patients with transfusional hemosiderosis: Results from a 5year observational study (ENTRUST)-Reference-Cited by-同舟云学术

Long-term safety and efficacy of deferasirox in young pediatric patients with transfusional hemosiderosis: Results from a 5year observational study (ENTRUST)

Published:2017-03-10 Issue:9 Volume:64 Page:e26507
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Vichinsky Elliott¹,El-Beshlawy Amal²,Al Zoebie Azzam³,Kamdem Annie⁴,Koussa Suzanne⁵,Chotsampancharoen Thirachit⁶,Bruederle Andreas⁷,Gilotti Geralyn⁸,Han Jackie⁸,Elalfy Mohsen⁹

Affiliation:

1. UCSF Benioff Children's Hospital & Research Center Oakland; Oakland California

2. Cairo University; Cairo Egypt

3. Sheikh Khalifa Medical City; Abu Dhabi UAE

4. Centre Hospitalier Intercommunal; Créteil France

5. Chronic Care Center; Hazmieh Lebanon

6. Songklanagarind Hospital; Songkhla Thailand

7. Novartis Pharma AG; Basel Switzerland

8. Novartis Pharmaceuticals; East Hanover New Jersey

9. Ain Shams University; Cairo Egypt

Funder

Novartis Pharmaceuticals Corporation

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pbc.26507/fullpdf

Reference28 articles.

1. Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF);Sanctis;Pediatr Endocrinol Rev,2004

2. Growth of children with β-thalassemia major;Low;Indian J Pediatr,2005

3. Short stature and failure of pubertal development in thalassaemia major: evidence for hypothalamic neurosecretory dysfunction of growth hormone secretion and defective pituitary gonadotropin secretion;Roth;Eur J Pediatr,1997

4. Novartis Pharmaceuticals UK Ltd Summary of Product Characteristics - EXJADE 125 mg, 250 mg, 500 mg dispersible tablets 2013 http://www.medicines.org.uk/emc/medicine/18805/SPC/

5. Novartis Pharmaceuticals EXJADE® (deferasirox) US Prescribing Information. 2015 http://www.pharma.us.novartis.com/product/pi/pdf/exjade.pdf

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Iron chelation therapy for children with transfusion‐dependent β‐thalassemia: How young is too young?;Pediatric Blood & Cancer;2024-05-16

2. Compliance and clinical benefit of deferasirox granule and dispersible tablet formulation in pediatric patients with transfusional iron overload: in a randomized, open-label, multicenter, phase II study;Haematologica;2023-10-19

3. Economic and clinical burden of managing transfusion-dependent β-thalassemia in the United States;Journal of Medical Economics;2023-07-24

4. Oxidative Stress and Renal Function in Pediatric Patients with Beta Thalassemia Major (β-TM) Receiving Deferiprone and Deferasirox: A Cross-Sectional, Single Center Study;Research Journal of Pharmacy and Technology;2023-03-31

5. Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years;Blood Advances;2023-02-21